Human Health Holdings Limited (Incorporated in Cayman Islands with limited liability) SHARE OPTION SCHEME Conditionally adopted by resolution of the shareholders of Human Health Holdings Limited dated [*] WARNING: The contents of this document have not been reviewed by any regulatory authority in Hong Kong. You are advised to exercise caution in relation to the offer of the Options. If you are in any doubt about any of the contents of this document, you should obtain independent professional advice. 1. DEFI ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 盈健醫療集團有限公司 呈交日期: 2025年11月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01419 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 HKD | | | 100,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 HKD | | | 100,000,000 | 本月底法 ...

Human Health Holdings Limited 盈健醫療集團有限公司 (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立之有限公司） (Stock Code: 1419) （股份代號：1419） Dear Non-registered Shareholders(1), 30 October 2025 Notification of publication of (i) 2025 Annual Report; (ii) the circular relating to the proposed general mandates to issue and repurchase shares, proposed re-election of directors, proposed re-appointment of auditor, expiry and proposed termination of 2016 share option scheme and proposed renewal and adoptio ...

Human Health Holdings Limited 盈健醫療集團有限公司 (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立之有限公司） Notification of publication of (i) 2025 Annual Report; (ii) the circular relating to the proposed general mandates to issue and repurchase shares, proposed re-election of directors, proposed re-appointment of auditor, expiry and proposed termination of 2016 share option scheme and proposed renewal and adoption of share option scheme and notice of 2025 annual general meeting (the "AGM circula ...

本人╱吾等， （附註1） Human Health Holdings Limited 盈健醫療集團有限公司 （於開曼群島註冊成立之有限公司） （股份代號：1419） 代表委任表格 （二零二五年十二月十日股東週年大會） | 地址為 | | | --- | --- | | 為盈健醫療集團有限公司（「本公司」）股本中每股0.01港元共 （附註2） | 股 | | （附註3） 股份之登記持有人，茲委任 大會主席或 | | | 地址為 | | 作為本人╱吾等之受委任代表，代表本人╱吾等出席於二零二五年十二月十日（星期三）上午十一時三十分假座香港中環皇后大道中99號 中環中心12樓02室舉行之股東週年大會（「大會」）及其任何續會，於會上發言並按本人╱吾等在適當欄內以「✓」標示的指示就下列決議案投票， 或若無相關指示，則由本人╱吾等之受委任代表酌情行事。 | | （附註5） 普通決議案 | （附註4） 贊 成 | （附註4） 反 對 | | --- | --- | --- | --- | | 1. | 省 覽、審 議 及 採 納 截 至 二 零 二 五 年 六 月 三 十 日 止 年 度 之 經 審 核 綜 合 財 務 報 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 通 告 全 部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Human Health Holdings Limited 盈健醫療集團有限公司 （於 開 曼 群 島 註 冊 成 立 之 有 限 公 司） （股 份 代 號：1419） 普通決議案 結算及交收系統持有或存放的本公司股份（「庫存股份」））；(ii)可轉換 為 本 公 司 股 份 的 額 外 證 券；及(iii)可認購任何本公司股份或可轉換證 券 的 額 外 購 股 權、認 股 權 證 或 類 似 權 利，以 及 作 出 或 授 出 可 能 需 行 使 該 等 權 力 的 要 約、協 議 及 購 股 權； 不得超過於本決議案獲通過當日本公司已發行股份（不 包 括 庫 存 股 份，如 有）數目之20%，而 上 述 批 准 須 受 相 應 限 制； 考慮及酌情通過下列決議案（不 論 有 否 修 訂）為 普 通 決 議 案： (d) 本公司不得發行可轉換為 ...

此乃要件 請即處理 閣下如 對本通函任何方面或 閣下應採取的行動 有任何疑問，應諮詢持牌證券商或註冊證 券機構、銀行經理、律師、專業會計師或其他專業顧問。 閣下如已售出或轉讓 名下所有盈健醫療集團有限公司股份，應立即將本通函及隨附的代表 委任表格送交買主或承讓人或經手買賣或轉讓的銀行、持牌證券商或註冊機構或其他代理， 以便轉交買主或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本通函全部或任何部分內容而產 生或因倚賴該等內容而引致的任何損失承擔任何責任。 Human Health Holdings Limited 盈健醫療集團有限公司 （於開曼群島註冊成立之有限公司） （股份代號：1419） (1)建議發行及購回股份之一般授權； (2)建議重選董事； (3)建議續聘核數師； (4)二零一六年購股權計劃屆滿及建議終止 以及建議續訂及採納購股權計劃； 及 (5)股東週年大會通告 本公司將於二零二五年十二月十日（星期三）上午十一時三十分假座香港中環皇后大道中99 號中環中心12樓02室召開股東週年大會（「股東週年大會」）， ...

Financial Performance - The company achieved a profit attributable to shareholders growth of approximately 8.9% compared to the fiscal year 2024, reflecting prudent strategies and operational rigor[10]. - The company recorded a revenue of approximately HKD 644.4 million for the fiscal year 2025, representing an increase of about 9.1% compared to HKD 590.8 million in fiscal year 2024[19]. - The net profit attributable to the company’s owners for fiscal year 2025 was approximately HKD 26.3 million, an increase of about HKD 2.1 million or 8.9% compared to fiscal year 2024[33]. - The effective tax rate increased from approximately 8.9% in fiscal year 2024 to about 11.1% in fiscal year 2025, due to an increase in taxable income[30]. - The group achieved a profit attributable to shareholders growth of approximately 8.9% year-on-year for the fiscal year 2025[34]. Revenue Growth by Division - Revenue from primary care services increased by approximately HKD 12.4 million or 3.1% to about HKD 410.8 million in fiscal year 2025, driven by an increase in patient visits and average spending per visit[19]. - Revenue from specialist medical services rose by approximately HKD 31.9 million or 23.8% to about HKD 165.8 million in fiscal year 2025, attributed to higher patient visits and average spending[20]. - Revenue from dental services increased by approximately HKD 9.3 million or 15.9% to about HKD 67.8 million in fiscal year 2025, mainly due to increased patient visits following the acquisition of a dental practice[20]. - The primary care division's revenue increased by about 3.1% compared to fiscal year 2024, maintaining stable performance[37]. - The specialty medical division generated revenue of approximately HKD 165.8 million in fiscal year 2025, representing a year-on-year growth of about 23.8%[39]. - The dental division's revenue, including the acquisition of Youde Dental, reached approximately HKD 67.8 million, reflecting a year-on-year increase of about 15.9%[41]. Strategic Initiatives and Expansion - The company plans to expand its primary care network by opening new medical centers and investing in digital platforms to enhance data management and customer engagement[16]. - The group has strategically opened new medical centers in Tsuen Wan, Tsim Sha Tsui, and Causeway Bay to improve accessibility and strengthen its presence in key areas[37]. - The group plans to enhance its specialized medical services, particularly in ophthalmology under the POLYEYE brand, by introducing new surgical techniques and hiring more professionals[66]. - Following the acquisition of Youde Dental, the group aims to strengthen its position in the dental services market and expand its service offerings[66]. - The group continues to maintain partnerships with the Hong Kong government, actively participating in various public health initiatives and community wellness programs[69]. Digital Transformation and Technology Integration - Digital transformation was a core focus, with the implementation of an integrated clinic operation system and a full-service marketing platform across most medical centers[14]. - The group achieved significant progress in digital transformation, implementing a comprehensive clinic operation system and a full-channel marketing platform to enhance customer engagement and satisfaction[46]. - The group integrates technology into operations to enhance care quality and efficiency, reflecting its commitment to improving healthcare services[46]. - The group will implement a comprehensive clinic operation system and a full-access marketing platform across most medical centers in fiscal year 2025, significantly improving clinical workflow coordination and appointment handling[67]. Community Health and Preventive Care - The company maintained close collaboration with the Hong Kong government on community health programs, highlighting its role in supporting healthcare infrastructure[15]. - The company emphasized preventive care and health education, promoting comprehensive health check-up packages through its health management center and online channels[13]. - The group continues to emphasize preventive care through advanced diagnostic health check packages and vaccination services[45]. - The flagship health center, H2, continues to enhance community health awareness through health seminars and workshops[43]. Human Resources and Talent Management - The professional team consists of 431 members, including general practitioners, specialists, and various healthcare professionals, ensuring comprehensive and patient-centered care[62]. - The company emphasizes the importance of attracting and nurturing professional talent to meet the growing patient demand and enhance its cross-departmental collaboration[68]. - The shortage of qualified healthcare professionals is a key issue impacting the healthcare industry, complicating recruitment and retention efforts[186]. - The group's financial performance may be affected if it fails to recruit or retain qualified professionals, as its business model relies on these teams[187]. Corporate Governance and Board Structure - The company has adopted the corporate governance code as its governance framework and has complied with all applicable code provisions for the fiscal year 2025, except for a deviation regarding the separation of the roles of Chairman and CEO[113][114]. - The board consists of six members, including three executive directors and three independent non-executive directors[120]. - The company has established procedures for directors to seek independent advice at reasonable requests, with costs borne by the company[119]. - The company has a policy for directors to retire and seek re-election at least every three years[130]. - The board has mechanisms to address conflicts of interest during decision-making processes[129]. Financial Position and Assets - The group’s net current assets as of June 30, 2025, are approximately HKD 383.9 million, a decrease from HKD 397.8 million as of June 30, 2024[73]. - The group’s interest-bearing bank borrowings as of June 30, 2025, amount to approximately HKD 16.8 million, with a mortgage loan of HKD 8.2 million due in 2036[73]. - The capital debt ratio as of June 30, 2025, is approximately 2.1%, down from 4.0% as of June 30, 2024[74]. - The company’s distributable reserves amounted to approximately HKD 206.7 million, with about HKD 11.4 million recommended for the final dividend[181]. Shareholder Communication and Dividends - The company proposed a final dividend of HKD 0.03 per share for the fiscal year 2025, an increase from HKD 0.028 in fiscal year 2024[176]. - The company maintains effective communication with shareholders through various channels, including interim and annual reports[169]. - The board is committed to ensuring that shareholders can access timely information to exercise their rights and participate in company affairs[168]. - The company has adopted a dividend policy that will be reviewed annually by the board, aiming to provide stable and sustainable returns to shareholders[171]. Industry Challenges and Risks - The group faces strategic risks due to rapidly changing community demands and ongoing global economic uncertainties post-pandemic[186]. - The group emphasizes the importance of maintaining a good reputation in the healthcare sector, as negative news could adversely affect its brand image[188]. - The group has not purchased, sold, or redeemed any of its listed securities in the fiscal year 2025[194].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 盈健醫療集團有限公司 呈交日期: 2025年10月2日 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01419 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 379,552,233 | | | | 379,552,233 | | 增加 / 減少 (-) | | | | | | | | | 本月底結存 | | | 379,552,233 | | 0 | | 379,552,233 | 第 2 頁 共 10 頁 v 1.1.1 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 ...

Human Health Holdings Limited 盈健醫療集團有限公司 （於開曼群島註冊成立的有限公司） 提名委員會 職權範圍 （董事會於2016年1月28日採納 及於 2022年12月15日及 2025年9月25日修訂及採納） 組織 1. 盈健醫療集團有限公司（「公司」）董事（「董事」）會（「董事會」）現議決於董事會 轄下成立一個提名委員會。 出席會議 成員 會議次數 6. 會議次數應不少於每年一次，並應按提名委員會工作所需加開會議。 會議通知 7. 會議通知須於開會前最少三個工作天（或所有提名委員會成員同意的其他較短時間）給予 所有提名委員會成員。 權力 刊登提名委員會職權範圍 12. 提名委員會的職權範圍應刊載於公司網站及「披露易」網站，用以解釋本委員會之角色 及董事會轉授予本委員的權力。 其他事項 2. 提 名 委 員 會 成 員 須 由 董 事 會 委 任 ，其 中 大 部 分 應 為 獨 立 非執行董事（「獨立非執行董 事」）。提名委員會的會議法定人數為兩人。 3. 提名委員會主席（「主席」）須由獨立非執行董事或董事會主席擔任。 4. 提名委員會成員可以親身出席方式或以其他電子通信設備形 ...